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Abbreviations: FS, Fraser syndrome; BM, basement membrane; BNAR, bifid nose, renal 
agenesis, and anorectal malformations syndrome; MOTA, Manitoba-oculo-tricho-anal syndrome; 
RU, response unit; TEM, transmission electron microscopy. 
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Abstract 
 
Fraser syndrome (FS) is a phenotypically variable, autosomal recessive disorder characterized by 
cryptophthalmus, cutaneous syndactyly and other malformations resulting from mutations in 
FRAS1, FREM2 and GRIP1. Transient embryonic epidermal blistering causes the characteristic 
defects of the disorder. Fras1, Frem1 and Frem2 form the extracellular Fraser complex, which is 
believed to stabilize the basement membrane (BM). However, several cases of FS could not be 
attributed to mutations in FRAS1, FREM2 or GRIP1, suggesting there is an additional genetic 
contribution to this disorder. AMACO, encoded by the VWA2 gene, has a very similar tissue 
distribution to the Fraser complex proteins. In mouse, AMACO is expressed in the developing 
lungs, kidney and skin where it is closely associated with the BM. In zebrafish AMACO is also 
associated with BMs, particularly in the developing fins, somite borders and the craniofacial 
region. Here, we show that AMACO deposition is lost in Fras1 deficient zebrafish and mice and 
that Fras1 and AMACO interact directly via their CSPG and P2 domains. Knockdown of vwa2, 
which alone causes no phenotype, enhances the phenotype of hypomorphic Fras1 mutant 
zebrafish. Together, our data suggest that AMACO represents a novel member of the Fraser 
complex. 
 4 
Introduction 
 
Fraser syndrome (FS; OMIM #219000) is a rare, autosomal recessive disorder characterized by 
cryptophthalmus, cutaneous syndactyly and variable other malformations (Slavotinek and Tifft, 
2002). Both the human syndrome and the closely related bleb mouse phenotype are caused by 
mutations in genes encoding proteins of the Fraser complex, FRAS1, FREM2 and, in mice, 
Frem1 (McGregor et al., 2003; Jadeja et al., 2005). The ectodomain of Fras1, which is shed from 
the cell surface, forms a ternary complex with Frem1 and Frem2 which reciprocally stabilizes 
these at the BM. The proteins are characterized by the presence of 12 CSPG repeats and single or 
multiple Calx-β domain(s) (Kiyozumi et al., 2007). In addition mutations in GRIP1, which 
encodes a cytoplasmic scaffolding protein, result in classical FS (Vogel et al., 2012). Indeed, it 
has been described that one of the mouse skin bleb mutants results from a mutation in Grip1, that 
Grip1 binds directly to Fras1, and that it is required for Fras1 localization at the BM (Takamiya et 
al., 2004; Long et al., 2008). Analysis of the mouse bleb mutants revealed transient embryonic 
epidermal blistering, particularly over the developing eyes and digits, as the likely primary defect 
leading to the later malformations characteristic of the human disorder (McGregor et al., 2003; 
Vrontou et al., 2003; Jadeja et al., 2005). The blisters result from a rupture just beneath the 
lamina densa of the BM and a separation of the dermis from the epidermis (McGregor et al., 
2003; Vrontou et al., 2003; Jadeja et al., 2005). Indeed, Fras1, Frem1 and Frem2 have been 
shown by immuno-gold EM to be localized on the dermal side of the lamina densa at islands 
normally associated with anchoring fibrils (Dalezios et al., 2007; Petrou et al., 2007a; Petrou et 
al., 2007b). The Fraser complex associated protein, Frem3, has a similar ultrastructural 
localization although this expression is independent of Fras1 (Petrou et al., 2007b).  
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Despite the identification of mutations in FRAS1, FREM2 and GRIP1 in both mice and humans 
with FS, a proportion of human cases remain unresolved suggesting that other genes may be 
involved (van Haelst et al., 2008; Vogel et al., 2012). Mutations in FREM1 were recently shown 
to result in bifid nose, renal agenesis, and anorectal malformations (BNAR) and Manitoba-oculo-
tricho-anal (MOTA) syndromes, two rare conditions with many similar phenotypic traits to FS, 
although milder (Alazami et al., 2009; Slavotinek et al., 2011). Recent analysis of ENU-induced 
mutants in zebrafish (Danio rerio) exhibiting transient blistering within the developing fins 
reveals functional conservation of the FS complex in lower vertebrates and suggests new 
potential FS-causing genes, such as hemicentin1 (hmcn1), encoding a large extracellular matrix 
protein (Carney et al., 2010) whose biochemical relationship to the FS complex is unclear. 
Via a biochemical candidate approach in zebrafish and subsequent analysis in mice, we have 
identified a novel member of the Fraser complex, AMACO, encoded by the VWA2 gene. 
AMACO (VWA2 protein) is a member of the von Willebrand factor A (VWA) domain 
containing protein superfamily (Whittaker and Hynes, 2002). The protein consists of an N-
terminal VWA domain, which is followed by a cysteine-rich domain, an epidermal growth factor 
(EGF)-like domain carrying elongated O-glucosylated and O-fucosylated glycan chains and two 
more VWA domains. At the C-terminus another EGF-like domain and a unique domain are 
present (Sengle et al., 2003; Gebauer et al., 2008). Analysis of mice and zebrafish revealed 
specific expression of AMACO at the BM of multiple tissues during development (Gebauer et 
al., 2010; Gebauer et al., 2009; Sengle et al., 2003). We demonstrate that AMACO is lost from 
both zebrafish and mouse mutants that lack Fras1 expression and that Fras1 and AMACO interact 
directly. Finally, we show that targeted knockdown of AMACO in zebrafish, which produces no 
overt phenotype alone, enhances the phenotype severity of hypomorphic Fras1 mutant zebrafish 
suggesting a supportive role for AMACO in the Fraser complex. 
 6 
Results 
 
AMACO is reduced or absent in Fras1 mutant zebrafish 
It was previously shown that AMACO is expressed during zebrafish development and exhibits a 
highly similar expression pattern to that of the FS genes, fras1, frem1a, frem1b, frem2a, frem2b 
and frem3 (Carney et al., 2010; Gebauer et al., 2010). We, therefore, analyzed the expression of 
AMACO in our panel of Fraser complex and related mutants: fras1
te262/te262
, fras1
tm95b/tm95b
, 
frem2a
ta90/ta90
, frem1a
tc280b/tc280b 
and hmcn1
tq207/tq207
 (Carney et al., 2010). AMACO is strongly 
expressed in the myosepta, the extracellular boundaries between the somites, and the developing 
caudal fin of 32 hpf wild-type zebrafish (Figure 1a). This expression in the myosepta and caudal 
fin is very similar to that of Fras1 (Figure 1a, inset). AMACO expression, however, was 
completely lost in null fras1
te262/te262
 fish (Figure 1b) and reduced in hypomorphic fras1
tm95b/tm95b
 
fish (Figure 1c) exactly correlating with Fras1 levels (Figure 1b and c, inset). By contrast, 
expression of AMACO was normal in frem2a
ta90/ta90
, frem1a
tc280b/tc280b 
and hmcn1
tq207/tq207 
fish 
(Figure 1d-f). The expression level of Fras1 was also normal in each of these mutant lines (Figure 
1d-f, inset). Quantification of immunoblots from whole zebrafish extracts confirmed the complete 
loss of AMACO in null fras1
te262/te262 
fish and a strong reduction in hypomorphic fras1
tm95b/tm95b 
fish. In the other mutants the level of AMACO remained normal or was only slightly reduced 
when compared to wild type levels. In situ hybridization and RT-PCR revealed that comparable 
levels of vwa2 mRNA are present in wild type and fras1 mutant fish (Suppl. 1), indicating that 
vwa2 transcription is not affected. 
 
 
AMACO is absent from Fras1
bl/bl 
mice 
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Next, we analyzed the expression of AMACO in Fras1
bl/bl 
mice. During mouse development 
AMACO is specifically localized at the BMs of skin, lung, heart, tooth germs and kidney (Sengle 
et al., 2003). Analysis of these regions in E14.5 Fras1
bl/bl 
mice revealed a complete loss of 
AMACO from the epidermal BM (Figure 2c) when compared to wild-type or Fras1
+/bl
 littermates 
(Figure 2a-b) even though laminin deposition was normal (Figure 2d-f). Similarly, analysis of a 
blistered region over the eye of a Fras1
bl/bl 
E14.5 embryo revealed a complete lack of AMACO 
expression (Figure 2g) even though laminin deposition demonstrated that a BM was still present 
as reported previously (Figure 2h; Vrontou et al., 2003). Analysis of other regions, including the 
eyelid, kidney and developing tooth germs at E14.5 also revealed a complete loss of AMACO 
deposition (Figure 2i-l and data not shown). 
 
 
AMACO and Fras1 co-localize beneath the lamina densa 
Previous ultrastructural examinations demonstrated that Fras1, Frem1, Frem2 and AMACO are 
all localized at the BM zone (Gebauer et al., 2009; Dalezios et al., 2007; Petrou et al., 2007a; 
Petrou et al., 2007b). To determine co-localization of Fras1 and AMACO, double 
immunoelectron microscopy labeling was performed on P0 mouse skin using secondary 
antibodies coupled to different sized gold particles. Both proteins were detected in distinct 
regions, anchoring plaques, in the dermis close to the BM (Figure 3a and b). These AMACO and 
Fras1 positive patches often occurred where anchoring fibrils fuse (Figure 3a). Although regions 
were observed where only one protein was present, mostly AMACO and Fras1 co-localized 
(Figure 3a and b). Collagen VII/Fras1 double immunoelectron microscopy showed that collagen 
VII, a major component of anchoring fibrils, occurs in proximity to Fras1 at anchoring plaques, 
but mostly at the opposite side of the plaque indicating that the two proteins may not interact 
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directly (Figure 3c). 
 
 
The AMACO fragment P2 binds to Fras1 CSPG repeats 
To test for direct interactions between AMACO and the Fras1 ectodomain we employed surface 
plasmon resonance assays. For AMACO, we generated recombinant full-length protein as well as 
protein fragments corresponding to AMACO domains P1, P2 and P3 (Figure 4a). The 
recombinant expression of the full-length Fras1 ectodomain repeatedly failed (data not shown). 
To overcome this problem, Fras1 cDNA fragments, representing the VWC-, Furin-like-, CSPG-, 
and Calx-β domains and the unique domain alone (Figure 4a) were cloned for protein production, 
but only the Furin-like-, CSPG-, and Calx-β domains were well expressed.  
Of these Fras1 fragments, we were only able to immobilize the CSPG domains on the sensor 
chip. When full-length AMACO was injected as soluble analyte at increasing concentrations (0–
400 nM) over the CSPG chip we obtained association and dissociation curves (Figure 4b) which 
could be fitted with a Langmuir 1:1 binding model and could calculate a dissociation constant 
(KD) of 75 nM. Of the three different domains (P1, P2, P3), binding to immobilized Fras1 CSPG 
was only seen with AMACO P2 (KD 151 nM) (Figure 4b). This binding is independent of the two 
unusual glycan chains on AMACO P2, as mutant forms lacking either one or both glycosylation 
sites still bound to immobilized Fras1 CSPG with similar KDs between 77 and 108 nM (data not 
shown). 
In the reverse set up (immobilization of AMACO P2 on the sensor chip and injection of the Fras1 
CSPG), we could confirm the binding between the AMACO P2 domain and the Fras1 CSPG 
domain (KD 42 nM; Figure 4c).  
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Loss of AMACO does not affect zebrafish development 
To analyze the role of AMACO during zebrafish development, we generated two translation 
inhibiting morpholinos, which were injected into the yolk of fertilized eggs. Neither morpholino 
gave an obvious phenotype (Figure 5a-d) even though immunofluorescence analysis of the 
morphants clearly showed a strong decrease in AMACO protein detection levels (Figure 5c, d, 
inset). In particular, caudal fin development was normal (Figure 5a, b). In agreement, the 
expression of Fras1 in developing caudal fin and myosepta was normal in vwa2 morphants 
(Figure 5c, d). Furthermore, knockdown of AMACO did not result in any obvious alteration in 
the structure of the pronephros and did not result in edema, which could indicate a failure in 
pronephros function (Drummond, 2005, data not shown). As AMACO is strongly expressed in 
the myosepta, potential ultrastructural changes in this region of the vwa2 morphants were studied 
by transmission electron microscopy (TEM). However, analysis of wild-type and morphant 
embryos at 48 hpf revealed no obvious differences in the architecture of the myosepta or in the 
connection to the neighbouring myotomes (Figure 5e and f). All injected larvae developed 
normally and showed no obvious defects at 80 hpf in overall morphology, fin development or 
development of the facial skeleton, areas which are particularly affected in Fras1 mutant 
zebrafish (Carney et al., 2010; Talbot et al., 2012) (Figure 5g and h). 
 
 
MO knockdown of AMACO in Fras1 hypomorphic zebrafish results in a more severe 
phenotype 
The loss of AMACO in Fras1 deficient zebrafish and mice suggests that Fras1 is required for 
AMACO deposition or protein stability. To determine if AMACO stabilizes Fras1 protein at the 
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BM, we injected a vwa2 specific MO into eggs resulting from an in-cross of fras1
+/tm95b
 fish 
(Figure 6). These fish carry the missense mutation G3816W in Fras1 and exhibit reduced, but 
detectable levels of Fras1 protein (Figure 1c, Figure 6b) and are therefore believed to represent a 
hypomorphic allele. When an uninjected in-cross of fras1
+/tm95b
 fish (n=415 (327=wt, 88=mut)) 
was compared to an in-cross of fras1
+/te262
 (null allele) fish (n=88 (65=wt, 23=mut)), 
fras1
tm95b/tm95b
 fish exhibit a milder caudal fin blistering phenotype as assessed by morphology 
(Figure 6a). In addition, injection of a missense MO into an in-cross of fras1
+/tm95b
 fish (n=389 
(308=wt, 81=mut)) had no effect on the severity of the caudal fin blistering phenotype (Figure 
6a). Injection of vwa2 MO into an in-cross of fras1
+/tm95b
 fish (n=500 (400=wt, 100=mut)), 
however, resulted in a more severe phenotype, to a comparable level to that of null fras1
te262/te262
 
fish (Figure 6a). Representative morphologies of the caudal fin at 34 hpf for each condition are 
shown in Figure 6b. Analysis of Fras1 expression revealed high levels in the myosepta and fin of 
wild-type fish, reduced levels in uninjected and missense MO injected fras1
tm95b/tm95b
 fish and a 
complete absence in fras1
te262/te262
 fish and fras1
tm95b/tm95b
 fish injected with vwa2 MO, 
corresponding to the severity of the phenotype (Figure 6b). Laminin levels were consistent under 
all conditions (Figure 6b). 
 
 
Discussion 
 
FS is a heterogeneous disorder affecting the development of the skin, eyes, digits and kidneys. 
Although mutations in FRAS1, FREM2 and GRIP1 have been identified in approximately 95% of 
all FS patients, additional genetic contributions to this disorder remain likely. The highly variable 
inter- and intra-familial phenotypic severity of FS also suggests the presence of genetic 
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modifiers. In this study, we have demonstrated that vwa2, a gene encoding AMACO, a BM 
associated extracellular protein containing three von Willebrand factor A (VWA) domains, 
contributes to the Fraser complex in zebrafish and mice. 
 
We could show that AMACO protein is completely absent in zebrafish and mouse mutants 
lacking Fras1, suggesting that Fras1 is crucial for the deposition or stabilization of AMACO. The 
vwa2 mRNA expression level in Fras1 mutant zebrafish is, in contrast, completely normal 
(Suppl. 1) suggesting specific protein stabilization. TEM further supports a direct interaction, as 
AMACO and Fras1 co-localize at a distance that is consistent with direct binding in islands 
beneath the lamina densa. Unfortunately, a comprehensive study of the interaction between 
AMACO and Fras1 was hampered by the fact that the ectodomain, the VWC domains and the 
unique domain of Fras1 could not be recombinantly expressed in sufficient amounts. However, 
AMACO fragments covering the whole sequence were expressed and surface plasmon resonance 
spectroscopy revealed direct binding between AMACO P2 and the CSPG domains of Fras1. 
 
Furthermore, we could demonstrate that knockdown of AMACO, which alone results in no 
morphological defects, can increase the phenotypic severity in hypomorphic Fras1 zebrafish. 
Upon AMACO knockdown the hypomorphic fish resemble the complete Fras1 knockout 
suggesting that, in addition to the requirement of Fras1 for AMACO deposition or stabilization, 
AMACO can stabilize Fras1. Reciprocal stabilization of Fras1, Frem1, Frem2 and possibly 
Frem3 has been suggested in mouse and zebrafish (Kiyozumi et al., 2006; Carney et al., 2010), 
whereas zebrafish Hmcn1, despite its co-expression with the FS genes and the similar phenotype 
of hmcn1 and fras1 mutants, is dispensable for Fras1 stabilization (Carney et al., 2010). So, 
although loss of AMACO alone does not cause a tissue integrity phenotype, our results 
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demonstrate that AMACO can also stabilize Fras1 at the BM, potentially in a redundant manner 
with other Fraser complex proteins.  
 
We currently do not know the nature of these potential redundant factors. For Frem2, the Fras1-
stabilizing effect was only revealed upon concomitant knockdown of the three closely related 
proteins, Frem2a, Frem2b and Frem3 (Carney et al., 2010). However, AMACO, although being a 
member of the VWA domain containing protein superfamily, does not belong to a distinct 
subfamily such as the matrilins or VWA domain containing collagens. Also, no direct AMACO 
paralogue has been annotated in the zebrafish genome. Therefore, it seems more likely that 
AMACO acts in partial functional redundancy with a more distantly related VWA protein. 
Nevertheless, the essential character of AMACO becomes apparent when Fras1 function is 
compromised. This indicates that interactions between several members of the Fraser complex 
are required for stabilization beneath the BM, with AMACO’s function to support this structural 
complex becoming vital when the multi-protein structure is compromised by reduced levels or 
activities of other components. Due to these particular genetic features of AMACO and its 
physical involvement in the Fraser complex both in zebrafish and mouse, VWA2 represents an 
interesting candidate for human mutation analysis in multigenic scenarios, possibly mediating a 
genetic predisposition for Fraser syndrome aetiology. 
 
 
Materials & Methods 
 
Zebrafish husbandry 
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Embryos were obtained from natural crosses and staged according to Kimmel et al., 1995. The 
mutant alleles pif
 te262
 (fras1), pif
 tm95 
(fras1), nel
 tq207 
(hmcn1), bla
 ta90
 (frem2a) and rfl
 tc280b
 
(frem1a) have been described previously (Carney et al., 2010). 
 
 
Antisense morpholino knockdown 
Morpholino antisense oligonucleotides (Supplement) were designed by and obtained from Gene-
Tools (Philomath, OR) and dissolved in distilled water to 1 mM stock solutions. Two different 
morpholinos covering the ATG translation start codon and the 5’ UTR of vwa2 were used, both 
resulting in translational inhibition. A five-mismatch morpholino was used as negative control. 
For injection, stocks were diluted to 0.1 mM in Danieau's buffer and phenol red (Nasevicius and 
Ekker, 2000). 0.5 nl of MO solution was injected into embryos at the 1–4 cell stage using glass 
needles pulled on a Sutter needle puller and a Nanoject injection apparatus (World Precision 
Instruments). 
 
 
Mouse lines 
E14.5 mouse embryos, generated from an in-cross of Fras1
+/bl
 mice and fixed in 4% 
paraformaldehyde (PFA), were obtained from Peter Scambler (UCL, London, UK). 
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Tissue-labeling procedures 
For whole-mount immunofluorescence analysis zebrafish were fixed in 4% PFA overnight at 4
o
C 
and washed with 1x PBS. Fish were then washed for several hours in dH20, blocked in 10% fetal 
calf serum (FCS) in 1x PBS, 0.5% Triton-X, incubated in primary antibody in 10% FCS 
overnight at 4
o
C, washed extensively in 1x PBS, 0.5% Triton-X, incubated overnight in 
secondary antibody in 10% FCS at 4
o
C, washed extensively in 1xPBS, 0.5% Triton-X and re-
fixed in 4% PFA. For immunofluorescence analysis on sections, tissue was dehydrated in a 
graded series of alcohols, cleared in Roti-Histol (Carl Roth) and embedded in paraffin wax. 
Immunofluorescence analysis was performed using standard protocols. Primary antibodies used 
were: rabbit anti-zebrafish AMACO (Gebauer et al., 2010), rabbit anti-zebrafish Fras1 (Carney et 
al., 2010), rabbit anti-mouse AMACO (Gebauer et al., 2009), and rabbit anti-laminin (Sigma 
Aldrich, L9393). Images were captured on a Zeiss Axiophot, Zeiss Apotome, Zeiss Confocal 
(LSM710 META) or Leica M165 FC compound microscope.  
For whole-mount alcian blue stainings, the embryos were washed in phosphate buffered saline 
and incubated in 0.1 mg/ml alcian blue in ethanol/acetic acid (4:1) for 2-6 h at 37°C. After 
clearing overnight by digestion with 50 mg/ml trypsin in 30% sodium tetraborate in water, the 
specimens were destained in 1% KOH/glycerol, flat-mounted between a slide and a coverslip and 
photographed using a Zeiss Axiophot microscope equipped with a Nikon digital camera. Whole-
mount in situ hybridization was performed as previously described (Gebauer et al., 2010) and 
photographed using a Zeiss Axiophot microscope equipped with a Nikon digital camera. 
 
 
Expression of full length AMACO and Fras1 fragments 
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Mouse cDNA fragments were generated by RT-PCR and cloned with 5’-terminal NheI and 3’-
terminal NotI restriction sites using oligonucleotide primers (Supplemental Table). The amplified 
PCR products were inserted into a modified pCEP-Pu vector containing an N-terminal BM-40 
signal peptide (Kohfeldt, 1997) followed by an N-terminal One-STrEP-tag (IBA GmbH) 
upstream of the restriction sites. The expression constructs were transfected into 293 EBNA cells 
with FuGENE HD (Roche) according to the manufacturer’s instructions. The cells were cultured 
in the presence of 10% FCS prior to harvest of cells and cell culture supernatant. After filtration 
and centrifugation of recombinant protein-containing supernatants for 1 h at 10,000 × g, these 
supernatant were applied to a Streptactin column (1.5 ml; IBA GmbH) and eluted with 2.5 mM 
desthiobiotin, 150mM NaCl, 100 mM Tris-HCl, pH 8.0. 
 
 
Fras1 antibody production 
Purified mouse Fras1 CSPG was used for guinea pig immunization. The antiserum was purified 
by affinity chromatography on a column with antigen coupled to CNBr-activated Sepharose (GE 
Healthcare). Specific antibodies were eluted with 0.1 M glycine, pH 2.5, and the eluate was 
neutralized with 1 M Tris-HCl, pH 8.8. Specificity was tested by western blot (Suppl. 2). The 
antibody was only used for immunoelectron microscopy. 
 
 
Surface plasmon resonance binding assays 
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Binding analyses were performed using a BIAcore2000 (GE Healthcare). All proteins were from 
mouse. Expression and purification of AMACO fragments has been described earlier (Gebauer et 
al., 2009) and purity of the proteins is documented in (Suppl. 3). Fras1 CSPG (2200 RUs), 
AMACO full-length (2300 RUs), AMACO P1 (2500 RUs), AMACO P2 (2400 RUs), and 
AMACO P3 (2500 RUs) were covalently coupled to carboxymethyldextran hydrogel 500M 
sensor chips (XanTec, Düsseldorf, Germany) using the amine coupling kit (GE Healthcare). 
Binding assays were performed at 25°C in 10 mM Hepes buffer, pH 7.4, containing 0.15 M 
NaCl, 3 mM EDTA, and 0.005% (v/v) P20 surfactant (HBS-EP buffer). Omission of EDTA and 
addition of 1mM MgCl2 and CaCl2 did not result in any change of binding events. Equilibrium 
dissociation constants (KD) were then calculated as the ratio kd/ka. Kinetic constants were 
calculated by nonlinear fitting of association and dissociation curves (BIAevaluation 4.1 
software). 
 
 
Protein extraction and western blot 
For protein extracts, 32 hpf wild type and morphant zebrafish larvae (50 each) were homogenized 
in 500µl 150mM NaCl, 2mM EDTA, 1% Nonidet P-40 and 50mM Tris, pH 7.4, put on ice for 15 
min, 1/3 volume of 4x SDS sample buffer (8% (w/v) SDS, 40% (v/v) glycerol, 0.2% (w/v) 
bromphenol blue, 250mM Tris-HCl, pH 6.8) was added, the samples were boiled for 5 min, 
centrifuged for 10 min. and subjected to 4-12% (w/v) SDS PAGE. Proteins were transferred to a 
nitrocellulose membrane and detected using polyclonal antibodies diluted in TBS/5% milk 
powder. Bands were detected by chemoluminescence immunoassay using a peroxidase-
conjugated swine anti rabbit secondary antibody (Dako). Image J was used for quantification of 
bands. 
 17 
 
 
Electron microscopy 
Wild type and morphant zebrafish larvae 48 hpf were anesthetized with 0.08% Tricaine, 
transferred into 6% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2, for immersion fixation 
and stored in this solution for 3 days at 4°C. Then the larvae were rinsed 2x 15 min in 0.1 M 
cacodylate buffer, pH 7.2, postfixed 120 min with 1% OsO4 in 0.1 M cacodylate buffer, pH 7.2, 
at room temperature in the dark, rinsed again, dehydrated with acetone and embedded in araldite 
CY212 (Durcupan ACM, Fluka). Ultrathin sections were cut at grey interference colour (25-30 
nm) with a 35°-diamond knife (Diatome) on an Ultracut E (Leica), stretched with chloroform 
vapour, mounted on 200 mesh copper grids (5 µm bar thickness) and contrasted 10 min with 
saturated (2%) uranyl acetate in 70% ethanol and 5 min with 0.2% aqueous lead citrate, pH 11.8. 
Microscopy was performed with a Zeiss EM109 (80 kV, 500 µm condenser 1 aperture, 200 µm 
condenser 2 aperture, 30 µm objective aperture) equipped with a temperature-stabilized wide 
angle YAC-CCD camera at the side entry port (1024x1024 pixel, 12-bit greyscale/pixel; 
info@trs-system.de). Magnification was calibrated with a cross grating replica (2160 lines/mm, d 
= 0.463 µm). 
 
 
Immunoelectron microscopy  
Newborn mouse skin was carefully sliced into 1 mm cubes, all including epithelium and dermis. 
Tissues were immersed in a combination of affinity purified rabbit AMACO-P3 antibody 
(Gebauer et al., 2009) or collagen VII antibody (Lunstrum et al., 1986) with guinea pig Fras1 
CSPG antibody (Suppl. 2) in Dulbecco's Modified Eagle Media (DMEM) at a ratio of 1:1:4 
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overnight at 4°C. Tissues were washed in DMEM for 4 hours at 4°C and then immersed in a 
combination of goat anti-rabbit 10-nm and goat anti-guinea pig 6-nm colloidal gold conjugates in 
DMEM at a ratio of 1:1:3 overnight at 4°C. The tissues were then rinsed extensively in DMEM, 
fixed in 1.5% glutaraldehyde/1.5% paraformaldehyde containing 0.5% tannic acid, post-fixed in 
1% OsO4, then dehydrated and embedded in Spurr's epoxy resin. Tissue was oriented so that 
cross sections of the dermal-epidermal junction would be obtained. Ultrathin sections were 
contrasted with uranyl acetate and lead citrate and examined using a FEI Tecnai G20 TEM.  
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Figure Legends  
 
Figure 1 - AMACO expression is affected in zebrafish models of Fraser syndrome. 
Immunofluorescence analysis of whole-mount zebrafish at 32 hpf reveals that (a) AMACO is 
strongly expressed in the myosepta and developing caudal fin of wild-type zebrafish, highly 
similar to the expression of Fras1 (inset). (b,c) By contrast, AMACO is completely absent from a 
zebrafish Fras1 null allele (fras1
te262/te262
)
 
(b), and partially lost from a hypomorphic Fras1 allele 
(fras1
tm95b/tm95b
) which exhibits some residual Fras1 expression (c). (d-f) AMACO expression is 
normal in null alleles for Frem2a (frem2a
ta90/ta90
; d), Frem1a (frem1a
tc280b/tc280b
; e) and 
Hemicentin1 (hmcn1
tq207/tq207
; f). Expression of Fras1 is also normal in each of these alleles (inset 
in d-f). Scale bar = 500 µm. (g,h) Quantitative AMACO immunoblot analysis and quantification 
in the zebrafish mutant strains shown in a-f.  In each case a pool of 50 fish of a given phenotype 
was extracted. In g, Ponceau loading control is given below. Antibodies are against zebrafish 
proteins (Gebauer et al., 2010; Carney et al. 2010). 
 
Figure 2 - AMACO expression is lost from Fras1 mutant mice. (a-f) Immunofluorescence 
analysis of the epidermis of E14.5 wild type (a,d), Fras1
+/bl
 (b,e) and Fras1
bl/bl
 (c,f) littermates 
reveals a complete loss of AMACO expression from the basement membrane of Fras1
bl/bl
 mice 
(c), whereas laminin expression is normal (f). (g-l) Similar analysis of other regions demonstrates 
the loss of AMACO from a blister over the eye of an E14.5 Fras1
bl/bl
 embryo (g) whereas laminin 
expression was still observed under the detached epidermis (j). Strong expression of AMACO 
was observed surrounding the developing tooth germs of E14.5 wild-type mice (h) but was 
completely lost from a Fras1
bl/bl
 littermate (i) despite laminin being normal (k,l). Scale bars = 50 
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µm. For generation and characterization of the mouse AMACO-P3 antibody see Gebauer et al., 
2009. 
 
Figure 3 - Fras1 and AMACO co-localize at the basement membrane. (a-c) For immuno-EM 
analysis, newborn mouse skin was immunolabeled enbloc with antibodies directed against mouse 
AMACO-P3, human collagen VII and mouse Fras1-CSPG. Secondary antibodies conjugated to 
gold particles of different size (Fras1: 6 nm; AMACO and collagen VII: 10 nm) were detected at 
anchoring plaques below the lamina densa (LD, black arrowheads). Often anchoring fibrils (AF, 
open arrowheads) are seen to intersect the anchoring plaques (AP). Collagen VII (arrows) and 
Fras1 often occur at opposite sides of anchoring plaques (c). (a and c) shows an overview and (b) 
shows selected anchoring plaques. The scale bar corresponds to 100 nm in (a and c) and 50 nm in 
(b).  
 
Figure 4 – AMACO and Fras1 interact directly. (a) Domain structures of Fras1 and AMACO. 
(S) signal peptide, (TM) transmembrane domain, the arrow indicates the furin cleavage site. (b, 
c) Surface plasmon resonance sensorgrams showing binding of different concentrations of 
soluble analytes to Fras1 CSPG (b) and AMACO P2 (c) coupled onto a chip. Full-length 
AMACO interacts with Fras1 CSPG, as does the AMACO P2 fragment. AMACO P1 and 
AMACO P3 do not interact (b). In the reversed orientation Fras1 CSPG interacts with AMACO 
P2 (c). All proteins were from mouse. 
 
Figure 5 - AMACO deficient zebrafish are phenotypically normal. (a-d) Injection of a vwa2 
specific morpholino has no effect on caudal fin development at 48 hpf (b) even though complete 
knockdown of the protein is observed (d). By contrast the levels of Fras1 in the developing fin of 
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vwa2 morphants are normal (inset in d). Antibodies were against zebrafish proteins (Gebauer et 
al., 2010; Carney et al. 2010). (e,f) TEM analysis at 48 hpf reveals no defect in the structure of 
the myosepta in vwa2 morphants (f) when compared to wild-type controls (e). (g,h) Similarly, no 
abnormalities can be observed in the craniofacial cartilages or general morphology of vwa2 
morphants at 80 hpf (h). My = myosepta; Pq, palatoquadrate; Ch, ceratohyal; Ih, interhyal; Hm, 
hyomandibular; Sy, symplectic. 
 
Figure 6 - vwa2 knockdown in Fras1 hypomorphic zebrafish increases the severity of the 
phenotype. (a) Chart depicting the relative severity of the blistering phenotype of Fras1 zebrafish 
injected with a missense morpholino (5mm) or a vwa2 specific MO. In all cases, mutant embryos 
were derived from heterozygous in-crosses, segregating in a normal Mendelian ratio. Only 
homozygotes are considered in the chart. Included are representative images of mild, moderate 
and severe blistering. Severe blistering was determined by a large number of caudal fin blisters 
(arrowheads) often extending further anterior within the dorsal region of the caudal fin. 
Associated extensive blistering of the caudal vein region was also observed (arrows). Moderate 
blistering involved fewer fin tip blisters of variable sizes and less although always some 
associated caudal vein blistering. Mild blistering was determined by a small number of fin tip 
blisters with no associated caudal vein blistering. Compare to b for a representative wild type fin. 
(b) Immunolocalization of Fras1 and laminin are also shown for each condition. The Fras-1 
antibodies are specific for zebrafish (Carney et al. 2010). 
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Supplemental Table 1 
Oligonucleotide sequences used for cDNA construction 
cDNA 
construct 
name forward primer (5’- 3’) name reverse primer (5’- 3’) 
AMACO 
full-length 
BK625 CAATGCTAGCCTTCAG
GAAGTGCATGTGAAC 
BK626 CAATGCGGCCGCTTACTTG
GCGGAGGACAGG 
Fras1 
ectodomain 
BK569 CAATGCTAGCGCTTGT
CTGTATCAGGGC 
BK570 CAATGCGGCCGCCTACTTA
TAGAGGGCATCTACTTTG 
Fras1 
VWC 
BK569 CAATGCTAGCGCTTGT
CTGTATCAGGGC 
BK609 CAATGCGGCCGCCTATACT
GGTGTGCAGTCTGG 
Fras1 
Furin 
BK610 CAATGCTAGCGTACAC
TGCCACCCAGAC 
BK611 CAATGCGGCCGCCTAGTCA
GTACAGTTTTCATTAGATG 
Fras1 
CSPG 
BK612 CAATGCTAGCGACAAA
ATGTACACTCCAAGTC 
BK613 CAATGCGGCCGCCTACTCC
TGGGTGAAGGTG 
Fras1 
CALX 
BK614 CAATGCTAGCGAGCAT
GTGAACTTGGG 
BK615 CAATGCGGCCGCCTAAATG
GGTGGCGCTG 
Fras1 
unique 
BK616 CAATGCTAGCGTAGTC
ACTCTTGCTGACTATG 
BK570 CAATGCGGCCGCCTACTTA
TAGAGGGCATCTACTTTG 
vwa2 
RT-PCR 
    
β-actin 
control 
    
 
Antisense morpholinos 
zAMACOas1 5’-CGGCTGCTTGAAGACATTTTTGTGC-3’ 
zAMACOas2 5’-CTTAGTGACACCGCAGTCCTGTTTA-3’ 
zAMACOmis1* 5’-CGCCTGGTTGAACACAATTTTCTGC-3’ 
*Mismatches in the target sequence are underlined. 
 
 
 
g h
1.0
0.8
0.6
0.4
0.2
0
relative 
units
(wt=1)
tq
20
7
tc
28
0b
ta
90
tm
95
b
te
26
2
w
t
tq
20
7
tc
28
0b
ta
90
tm
95
b
te
26
2 w
t





Supplemental figure 1. Normal expression of vwa2 in fras1 mutant fish. (A) In situ hybridization reveals 
comparable levels of vwa2 mRNA in the developing caudal fin of wild type and fras1te262/te262 null fish 
at 30 hpf. (B) RT-PCR reveals comparable levels of vwa2 mRNA in whole wild type and fras1 mutant 
fish. te262, fras1 ; tm95b, fras 1 hypomorph,  ta90, frem1a mutant; tc280b, frem2a mutant; tq207, 
hmcn1. b-actin was used as control. RT-PCR was performed as previously described (Gebauer et al., 
2010). The primers are given in Supplemental Table 1.
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A
B
Supplemental figure 2 Specificity of the guinea pig Fras1 CSPG antibody. A, immunoblot analysis. Cell culture 
supernatants from wild-type 293EBNA cells (wt-293EBNA), from 293EBNA cells transfected with the Fras1 CSPG 
domain (CSPG 293EBNA), 20 ng of affinity purified Fras1 CSPG  (20 ng CSPG) and a limb bud extract from 18.5-
day- old mouse embryos were separated by reducing (+SH) and non-reducing (-SH) SDS-PAGE on 4-12% 
polyacrylamide gels and transferred to nitrocellulose. The blot was subsequently developed with the affinity-
purified Fras1 CSPG antibody.  On the right, Ponceau staining is shown to demonstrate protein load. Limb buds 
were extracted with TBS. B. Immunofluorescence staining. A paraffin-embedded section of skin from a 14.5  mouse 
embryo was stained with the affinity-purified guinea pig antibody directed against the murine Fras1 CSPG domains 
followed by incubation with  Alexa 488 (red) coupled secondary antibodies. Fras1 is only detected in the basement 
membrane.
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Supplemental figure 3. Recombinant expression of proteins used for SPR analysis. Affinity purified 
proteins were submitted to SDS-PAGE (4-12% polyacrylamide gels in (A) and 12% gels in (B)) under 
reducing conditions and stained with Coomassie brilliant blue.  The Fras1 fragments CSPG, Furin and 
Calx and AMACO full-length (fl) carry a One-STrEP-tag, AMACO wild type fragments (P1–P3) and 
mutant AMACO-P2 lacking O-fucosylation and O-glucosylation sites (Ägluc, Äfuc,  ) carry a 
8X his tag. Bands of the expected size are marked by asteriscs. Lower migrating bands in CSPG, 
AMACO fl and AMACO P1 contain degradation products, the bands marked by # in the lanes for 
AMACO P2 contain calsyntenin 1. 
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